^
    6d
    NETTER-3: Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (clinicaltrials.gov)
    P3, N=240, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Sep 2030 --> Dec 2028
    Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    Lutathera (lutetium Lu 177 dotatate) • Signifor (pasireotide) • octreotide acetate
    7d
    Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial (clinicaltrials.gov)
    P2, N=100, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2026 --> Apr 2029
    Trial completion date • Trial primary completion date
    |
    sunitinib • everolimus • Cabometyx (cabozantinib tablet) • Lutathera (lutetium Lu 177 dotatate)
    8d
    LuPARP: 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (clinicaltrials.gov)
    P1, N=18, Completed, Vastra Gotaland Region | Active, not recruiting --> Completed
    Trial completion
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)
    8d
    Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Fundación de investigación HM | Phase classification: P2 --> P1/2
    Phase classification
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)
    8d
    Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. (clinicaltrials.gov)
    P1, N=104, Recruiting, RayzeBio, Inc. | Not yet recruiting --> Recruiting | Trial completion date: Oct 2032 --> Apr 2033
    Enrollment open • Trial completion date • First-in-human
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    8d
    RYZ101-101: Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, RayzeBio, Inc. | N=49 --> 21 | Trial completion date: Mar 2029 --> Jul 2027 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • SSTR (Somatostatin Receptor)
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
    9d
    The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [177Lu]Lu-DOTA-TATE: A post-authorisation safety study. (PubMed, J Neuroendocrinol)
    Trial registration: EudraCT, 2019-004073-76. Registered 20/08/2020.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)
    9d
    Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors (clinicaltrials.gov)
    P1/2, N=65, Recruiting, Nationwide Children's Hospital | Trial completion date: Nov 2027 --> Nov 2033 | Trial primary completion date: Nov 2027 --> Nov 2028
    Trial completion date • Trial primary completion date
    |
    Lutathera (lutetium Lu 177 dotatate)
    14d
    A sstR2-targeted radiohybrid theranostic agent for PET imaging and β- therapy with excellent preclinical performance. (PubMed, Npj Imaging)
    The rh-theranostic agent demonstrates similar in vitro behavior compared to the gold standards [177Lu]Lu-DOTA-TATE and SiFAlin-TATE, along with an exceptionally high tumor uptake (53.58 ± 5.51% ID/g for the radiofluorinated version) after 1 h post-injection in AR42J tumor-bearing mice, making it ideal for imaging. Moreover, clearance from normal tissues and considerable tumor retention (10.32 ± 7.04%ID/g) for [177Lu]Lu-TATE4 were observed at 24 p.i., suggesting good therapeutic applicability.
    Preclinical • Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    Lutathera (lutetium Lu 177 dotatate)
    15d
    ALPHAMEDIX 02: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, Orano Med LLC | Trial completion date: Oct 2028 --> Dec 2030 | Trial primary completion date: Oct 2028 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (SAR447873)
    18d
    FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto. (PubMed, Appl Radiat Isot)
    This FAERS analysis characterizes agent-specific safety profiles, informing pharmacovigilance strategies. Mechanistic profiling of adverse drug reactions optimizes evidence-based treatment, enhancing medication safety and refining benefit-risk profiles in clinical practice.
    Journal • Adverse events
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • SSTR (Somatostatin Receptor)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Lutathera (lutetium Lu 177 dotatate)
    22d
    Is Peptide Receptor Radionuclide Therapy Effective in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer?-A Case Report. (PubMed, Niger J Clin Pract)
    This case highlights the limited therapeutic efficacy of PRRT in RAIR-DTC, despite favorable imaging characteristics. It underscores the need for better patient selection and further research to clarify the role of PRRT in this population.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)